Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient’s smartphone proves to be non-inferior to clinic data capture
Open Access
- 22 February 2025
- journal article
- Published by Taylor & Francis in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
- Vol. 26 (5-6) , 495-506
Abstract
To investigate self-assessment of the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) using the patient's smartphone and to analyze non-inferiority to clinic assessment. In an observational study, ALSFRS-R data being remotely collected on a mobile application (App-ALSFRS-R) were compared to ALSFRS-R captured during clinic visits (clinic-ALSFRS-R). ALS progression rate (ALSPR)-as calculated by the monthly decline of ALSFRS-R-and its intrasubject variability (ALSPR-ISV) between ratings were used to compare both cohorts. To investigate non-inferiority of App-ALSFRS-R data, a non-inferiority margin was determined. A total of 691 ALS patients using the ALS-App and 1895 patients with clinic assessments were included. Clinical characteristics for the App-ALSFRS-R and clinic-ALSFRS-R cohorts were as follows: Mean age 60.45 (SD 10.43) and 63.69 (SD 11.30) years (p < 0.001), disease duration 38.7 (SD 37.68) and 56.75 (SD 54.34) months (p < 0.001) and ALSPR 0.72 and 0.59 (p < 0.001), respectively. A paired sample analysis of ALSPR-ISV was applicable for 398 patients with clinic as well as app assessments and did not show a significant difference (IQR 0.12 [CI 0.11, 0.14] vs 0.12 [CI 0.11, 0.14], p = 0.24; Cohen's d = 0.06). CI of IQR for App-ALSFRS-R was below the predefined non-inferiority margin of 0.15 IQR, demonstrating non-inferiority. Patients using a mobile application for remote digital self-assessment of the ALSFRS-R revealed younger age, earlier disease course, and faster ALS progression. The finding of non-inferiority of App-ALSFRS-R assessments underscores, that data collection using the ALS-App on the patient's smartphone can serve as additional source of ALSFRS-R in ALS research and clinical practice.Keywords
All Related Versions
Funding Information
- Boris Canessa ALS Stiftung
This publication has 38 references indexed in Scilit:
- Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 monthsMuscle & Nerve, 2024
- Categorization of the amyotrophic lateral sclerosis population via the clinical determinant of post‐onset ΔFS for study design and medical practiceMuscle & Nerve, 2024
- Neurofilament light‐chain response during therapy with antisense oligonucleotide tofersen in SOD1‐related ALS: Treatment experience in clinical practiceMuscle & Nerve, 2023
- Clinical and neurophysiological biomarkers of disease progression in amyotrophic lateral sclerosisMuscle & Nerve, 2022
- Improved ALS clinical trials through frequent at‐home self‐assessment: a proof of concept studyAnnals of Clinical and Translational Neurology, 2020
- Design and results of a smartphone‐based digital phenotyping study to quantify ALS progressionAnnals of Clinical and Translational Neurology, 2019
- ALSFRS-R score and its ratio: A useful predictor for ALS-progressionJournal of the Neurological Sciences, 2008
- Das Strengthening the Reporting of Observational Studies in Epidemiology (STROBE-) StatementDie Innere Medizin, 2008
- ALSFRS and appel ALS scores: Discordance with disease progressionMuscle & Nerve, 2008
- The Amyotrophic Lateral Sclerosis Functional Rating ScaleArchives of Neurology, 1996